K.S. Gajiwala

机构：Pfizer (United States), PRX Research · ORCID：0000-0003-0338-2529

发表论文 85 篇 · 总被引 12709 次 · h-index 29

代表论文

• An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19 (2021 · Science · 被引 1966)
• Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19 (2020 · Journal of Medicinal Chemistry · 被引 535)
• Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate ( R )-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2 H )-one (PF-06821497) (2017 · Journal of Medicinal Chemistry · 被引 129)
• Proteome-wide Map of Targets of T790M-EGFR-Directed Covalent Inhibitors (2017 · Cell chemical biology · 被引 103)
• Conserved RNA-binding specificity of polycomb repressive complex 2 is achieved by dispersed amino acid patches in EZH2 (2017 · eLife · 被引 102)
• Dissecting the molecular determinants of clinical PARP1 inhibitor selectivity for tankyrase1 (2020 · Journal of Biological Chemistry · 被引 96)